Epigenetic Aging Clocks Reveal How Stroke Accelerates Cognitive Decline

Every year, millions of stroke survivors face an unwelcome and often invisible aftermath: their minds do not fully return to what they were. Cognitive impairment after stroke is one of the strongest known stepping stones toward dementia, yet the biological machinery connecting a vascular insult in the brain to the slow erosion of memory and thinking has remained frustratingly opaque. A new study published in PLOS Aging and Health by Reem Waziry of the University of Florida and colleagues at Columbia University and Harvard now offers one of the most detailed causal maps to date of that machinery, showing that the damage may travel through two intertwined channels: the speed at which our bodies age biologically, and the state of our immune and inflammatory systems.

The research drew on the Health and Retirement Study, a landmark longitudinal survey that has followed more than 37,000 American adults aged 50 and older since 1992. For this analysis, the team focused on 3,467 individuals who had reported stroke status at the twelfth survey wave, consented to blood draws in the 2016 Venous Blood Study, and completed cognitive assessments through wave 15. The cohort had a median age of 71 years, 59 percent were women, and 295 participants had experienced a stroke. Rather than treating stroke as a single moment in time, the researchers framed lifetime stroke burden as their exposure, then asked how it propagated forward into cognition measured in 2018 and again in 2020.

The methodological centerpiece of the study is the four-way decomposition, a modern causal inference framework rooted in non-parametric structural equation models. Instead of merely asking whether stroke correlates with worse cognition, the decomposition splits the total effect of stroke on cognition into distinct components: a controlled direct effect that bypasses intermediate biology, pure indirect effects that flow through a mediator, and two interaction terms that capture how stroke and the mediator amplify each other. In plain terms, the approach distinguishes between pathways where the mediator carries the stroke signal forward and pathways where the stroke only does damage because it meets a susceptible biological environment. Standard errors were computed from 1,000 bootstrapped samples, and a Bonferroni-corrected threshold of 0.002 guarded against spurious findings across dozens of comparisons.

The mediators themselves represent some of the most advanced tools in contemporary geroscience. Using DNA methylation data, the chemical marks deposited on DNA that shift predictably with age, the team quantified biological aging with eight epigenetic clocks, including the Horvath pan-tissue clock built from 353 CpG sites, the Hannum clock based on 71 sites, the Levine PhenoAge clock, and GrimAge, a composite measure trained in the Framingham Heart Study that estimates epigenetic surrogates of plasma proteins such as GDF-15, cystatin C, leptin and plasminogen activator inhibitor 1, along with cumulative smoking exposure. On top of the epigenetic layer, the researchers measured a panel of inflammatory cytokines, including interleukin-6, interleukin-1 receptor antagonist, interleukin-10, tumor necrosis factor receptor 1 and transforming growth factor-beta, alongside immune cell counts covering basophils, eosinophils, lymphocytes, monocytes, neutrophils and total white blood cells.

The first striking finding is that stroke survivors were biologically older than their calendar years. Their median GrimAge was 74.5 years compared with 70 years among participants who had never had a stroke, an acceleration consistent with the idea that cerebrovascular disease is not merely a disease of aged vessels but a manifestation of accelerated systemic aging. When the team then traced how stroke affected cognition at wave 14, the short-term outcome, they found that biological age carried a substantial indirect burden: the pure natural indirect effect through biological aging was −0.47 points on the total cognition score, with a P value below 0.001. A nearly identical signal appeared for intermediate-term cognition measured in 2020, with a pure natural indirect effect of −0.48. Mediation through biological aging accounted for roughly 28 percent of the stroke effect on short-term cognition and 23 percent on intermediate-term cognition.

Among the immune and inflammatory markers, one molecule towered over the rest. Transforming growth factor-beta, a cytokine with near-omnipresent signaling roles in cell growth, differentiation, apoptosis, wound healing, angiogenesis and tissue remodeling, displayed a powerful interactive effect rather than a purely mediative one. The reference interaction effect for TGF-beta on short-term cognition was −2.09, with a 95 percent confidence interval spanning −3.41 to −0.78 and P below 0.001, meaning that the harm stroke inflicted on cognition was strongly modified by the level of this cytokine when the mediator sat at its natural, unexposed value. The effect on intermediate-term cognition was attenuated at −1.72 and did not survive the strict Bonferroni correction, suggesting the interactive damage is most pronounced in the months shortly after the vascular insult.

Weaker but statistically detectable mediation emerged through the immune compartment as well. White blood cell count carried a small indirect effect on short-term cognition of −0.02 with P equal to 0.03, and TNF receptor 1 showed a comparable marginal signal. More intriguingly, when biological aging, inflammatory cytokines and immune markers were modeled together as a joint mediator set, the combined indirect effect reached −0.42 on short-term cognition, indicating that these systems act in concert rather than in isolation. The authors point to the concept of inflamm-aging, the chronic low-grade inflammation that accumulates with age, as a plausible link: TGF-beta is inversely related to epigenetic aging clocks, it halts the cell cycle at the G1 phase, and epigenetic regulators can influence its activation and downstream signaling, creating feedback loops between aging biology and inflammatory control.

Mechanistically, the findings make biological sense. Ischemic injury releases danger-associated molecular patterns that activate Toll-like receptors, recruit innate and adaptive immune cells and ignite the complement system. TGF-beta, in turn, recruits macrophages that generate additional cytokines such as interleukin-1, tumor necrosis factor-alpha and fibroblast growth factor, fueling a positive feedback loop at the injury site, while reactive oxygen species amplify TGF-beta activity through thrombospondin-1. Because the cytokine governs tissue and vascular remodeling, the authors argue that regulating TGF-beta after cerebrovascular injury could become a therapeutic strategy, timed to the window when its interaction with the stroke insult does the most cognitive harm. Epigenetic mechanisms may also connect to classical Alzheimer pathology, since DNA methylation variability has been linked to amyloid-beta and neurofibrillary tangles in brain tissue.

The study is not without limitations, which the authors confront directly. Residual confounding can never be fully eliminated in observational data, stroke was ascertained by self-report of a physician diagnosis, the follow-up window for cognition was relatively short, and the median age of 71 means the results cannot be extrapolated to younger populations. Severe disability may also have prevented some stroke survivors from participating in cognitive testing. Yet the evidence base is reassuring in key respects: self-reported stroke in the Health and Retirement Study correlates strongly with hospital records, and sensitivity analyses adjusting for race, education, baseline cognition and log-transformed biomarkers produced comparable or attenuated but consistent estimates.

The significance of the work lies in its reframing of what happens after a stroke. Rather than viewing post-stroke cognitive decline as a fixed consequence of brain injury, the unified causal framework portrays it as a dynamic interplay between an accelerated aging process that can be measured in a blood sample and an inflammatory milieu that can, in principle, be therapeutically modulated. Because both the exposure and the proposed mediators are potentially manipulable through non-invasive means, DNA methylation clocks combined with routine immunoinflammatory blood markers could one day serve as prognostic dashboards, identifying which stroke survivors are aging fastest and which immune checkpoints are most likely to erode their cognition. In a population where stroke remains a leading cause of acquired dementia, turning biological aging and TGF-beta from silent accomplices into monitored, modifiable targets could reshape how medicine protects the aging brain.

Subject of Research: The causal roles of DNA methylation-based biological aging, inflammation and immunity in post-stroke cognition

Article Title: The role of DNA methylation-based biological aging, inflammation and immunity in post-stroke cognition: A unified causal framework

Article References: Waziry, R., Miles, C. H., Williams, O., & Tiemeier, H. (2026). The role of DNA methylation-based biological aging, inflammation and immunity in post-stroke cognition: A unified causal framework. PLOS Aging and Health, 1(3), e0000033. https://doi.org/10.1371/journal.page.0000033

Image Credits: AI Generated

DOI: 10.1371/journal.page.0000033

Keywords: stroke, cognition, biological aging, DNA methylation, epigenetic clocks, GrimAge, TGF-beta, inflammation, immunity, causal mediation, Health and Retirement Study, cognitive decline